Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $115 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which increased confidence in the second half of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $113 from $104 at Raymond James
- Zimmer Biomet price target raised to $96 from $91 at UBS
- Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained
- Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns
- Zimmer Biomet Reports Strong Q2 2025 Results